基于血液的T790M基因分型在表皮生长因子受体突变的非小细胞肺癌中的意义及其他影响 - Suppr

Implications of Blood-Based T790M Genotyping and Beyond in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

作者信息

Rosell Rafael, Karachaliou Niki

机构信息

Hospital Germans Trias i Pujol, Badalona; and Autonomous University of Barcelona, Spain

Germans Trias i Pujol Health Sciences Research Institute, Badalona; and University Hospital Sagrat Cor, Barcelona, Spain.

出版信息

J Clin Oncol. 2016 Oct 1;34(28):3361-2. doi: 10.1200/JCO.2016.68.3458. Epub 2016 Jul 18.

DOI:10.1200/JCO.2016.68.3458

PMID:27432918

Abstract

摘要

相似文献

Implications of Blood-Based T790M Genotyping and Beyond in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

J Clin Oncol. 2016 Oct 1;34(28):3361-2. doi: 10.1200/JCO.2016.68.3458. Epub 2016 Jul 18.

Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.

Clin Chim Acta. 2013 Oct 21;425:119-24. doi: 10.1016/j.cca.2013.07.012. Epub 2013 Jul 23.

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.

BMC Cancer. 2016 Nov 8;16(1):864. doi: 10.1186/s12885-016-2902-0.

Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.

Biochem Biophys Res Commun. 2013 Feb 15;431(3):623-9. doi: 10.1016/j.bbrc.2012.12.070. Epub 2012 Dec 22.

Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.

Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30.

TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.

PLoS One. 2015 Jun 19;10(6):e0129838. doi: 10.1371/journal.pone.0129838. eCollection 2015.

Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.

Cancer. 2013 Dec 15;119(24):4325-32. doi: 10.1002/cncr.28364. Epub 2013 Sep 16.

Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer.

Cancer Genet. 2015 May;208(5):271-8. doi: 10.1016/j.cancergen.2014.12.005. Epub 2015 Jan 6.

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

JAMA Oncol. 2016 Aug 1;2(8):1014-22. doi: 10.1001/jamaoncol.2016.0173.

Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.

Clin Lung Cancer. 2017 Nov;18(6):698-705.e2. doi: 10.1016/j.cllc.2017.05.004. Epub 2017 May 10.

引用本文的文献

Dynamic Assessment of Tissue and Plasma -Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs.

Int J Mol Sci. 2022 Sep 26;23(19):11353. doi: 10.3390/ijms231911353.

EGFR first- and second-generation TKIs-there is still place for them in -mutant NSCLC patients.

Transl Cancer Res. 2019 Jan;8(Suppl 1):S23-S47. doi: 10.21037/tcr.2018.10.06.

Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAM EGFR V2 and NGS Technologies.

Mol Diagn Ther. 2021 Mar;25(2):239-250. doi: 10.1007/s40291-021-00515-9. Epub 2021 Mar 3.

The Dynamic Use of Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients.

Dis Markers. 2019 Jan 23;2019:7954921. doi: 10.1155/2019/7954921. eCollection 2019.

Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma.

PLoS One. 2018 Nov 16;13(11):e0207001. doi: 10.1371/journal.pone.0207001. eCollection 2018.

Possible application of circulating free tumor DNA in non-small cell lung cancer patients.

J Thorac Dis. 2017 Oct;9(Suppl 13):S1364-S1372. doi: 10.21037/jtd.2017.09.59.

Treating mutation resistance in non-small cell lung cancer - role of osimertinib.

Appl Clin Genet. 2017 Jul 26;10:49-56. doi: 10.2147/TACG.S103471. eCollection 2017.

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).

Oncotarget. 2017 Jul 18;8(29):47305-47316. doi: 10.18632/oncotarget.17625.

Liquid Biopsy in Non-Small Cell Lung Cancer.

Front Med (Lausanne). 2016 Dec 23;3:69. doi: 10.3389/fmed.2016.00069. eCollection 2016.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Implications of Blood-Based T790M Genotyping and Beyond in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献